icon-account icon-glass
FREE Podcast Series with Medical Advisor Dr. Bill Code
Connect

Effexor WITHDRAWAL

Effexor Withdrawal and Tapering Help

Call us for Effexor withdrawal information   

Do you need Help to Get Off Effexor due to the extremely debilitating Effexor Withdrawal Symptoms? Our Cofounder went cold-turkey from Effexor and after recovering cofounder our nonprofit 15 years ago to help others recover with a proven holistic approach that provides relief that allows you to Get Off Effexor properly.  Our at-home program has been used in 78 countries with tremendous success so you are healing as you slowly Wean Off Effexor.  Effexor Withdrawal Help is possible and you can Wean Off Effexor while easing symptoms as you slowly Wean Off Effexor.  No need to suffer. If you need Help to Get Off Effexor, Contact our nonprofit for a FREE consultation.

read more...

SUCCESSFUL CHOICES YOU CAN MAKE RIGHT NOW

START OUR EFFEXOR WITHDRAWAL PROGRAM

    LEARN MORE ABOUT OUR IN-HOME WITHDRAWAL PROGRAM

      LIVE CHAT

        EMAIL

        TALK TO A REAL PERSON 866-605-2333 (toll-free) 

          REACH OUT FORM 

            "I am writing to let you know that I have successfully completed my taper from 7+ years of 150 mg of EFFEXOR XR using your  withdrawal program. Thank you so much for your help."  - Laura (Effexor Withdrawal Success Story)

            Enter Discount Code  ADFree for FREE Ground Shipping on your Withdrawal Program  *USA & Canada Only

            HOW IT WORKS:

            Our Effexor weaning program is a slow taper that allows you to safely step down from Effexor under the guidance of our Prescription Experts, your Physician and Pharmacist. The Pre-Taper is for Symptom Relief. You will not wean Effexor until you feel better. This is where our Advanced Nutraceuticals are critical. Point of Return provides healthy, Drug-Free Strategies to help minimize Effexor withdrawal symptoms to improve mental and physical well-being.

            Our areas of expertise are Antidepressants, Benzodiazepines, Sleeping Pills and Painkillers on a case-by-case basis. Our In-Home programs are individualized based on your situation. An assessment is done once you start the Effexor Withdrawal Program which allows us to individualize your gameplan based on age; length of time on the medications; health challenges; lifestyle, stress levels; additional medications; and interactions. Don't Wean Effexor alone, work with our Prescription Drug Experts.

            Imagine being Free of Effexor Addiction 

            - Proven Program completed In-Home with Expert Guidance

            - Slowly Wean off Effexor

            - All-Natural Nutraceuticals to help Ease Effexor Withdrawal Symptoms

            - Professional information on interactions

            - Free Mentoring on our 24/7 private Discussion Board

            - Free Assessment Upon Starting our Program (a $400 value)

                PROVEN RESULTS

                SIMPLE - NATURAL - SAFE - EFFECTIVE

                EFFEXOR WITHDRAWAL SUCCESS STORIES

                Michel - Effexor Withdrawal Success Story

                I really appreciate the gift of being able to be off the SSRI's because of the negative side effects they had. Thank you!!! More... 

                Michel (Effexor Withdrawal Success Story)

                Ana - Effexor Withdrawal Success Story

                I am drug-free now and my mind is clear and sharp. The nerve pain is much, better and my life is full. I plan to continue taking the nutrients forever. More...

                Anna (Effexor Withdrawal Success Story)

                Laura - Effexor Withdrawal Success Story

                I didn't know what a fighter I was until now that I look back on this past year and realize that I never once thought about quitting the program. More...

                Laura (Effexor Withdrawal Success Story)

                REACH OUT

                Message sent, thanks!

                Effexor Resource Center

                EFFEXOR SIDE EFFECTS, WITHDRAWAL SYMPTOMS AND ADVERSE REACTIONS ( link | pdf )

                EFFEXOR HISTORY AND INFO  ( link | pdf )

                EFFEXOR REFERENCES AND FDA INFO ( link | pdf )

                Effexor Info and History

                Effexor (Venlafaxine) is an SNRI (Selective Serotonin-Norepinephrine Reuptake Inhibitor) that was introduced by Pfizer in 1993. By 2007, Effexor was the sixth most commonly prescribed antidepressant on the U.S. market. Sales of Effexor XR represent 17% of Wyeth Laboratories profit with nearly $ billion per year.

                Effexor was one of the top 25 most prescribed medications used in prisons by The Department of Corrections.

                Effexor can increase eye pressure so patients with glaucoma should have more frequent eye checks.  There are few well-controlled studies of Effexor in pregnant women but a study released in May 2010 (Canadian Medical Association Journal) suggested it doubled the risk of miscarriage.

                At dosages less than 150mg per day, it acts primarily on Serotonin, while at moderate dosages of 150-300mg Effexor affected both Serotonin and Norepinephrine. At dosages above 300mg, Effexor also exerted it effect on Dopamine.

                Serotonin is found primarily in the gastrointestinal tract, blood platelets and central nervous system. Norepinephrine has multiple roles including as a hormone and neurotransmitter and is most responsible for vigilant concentration in contrast to Dopamine that is most responsible for cognitive alertness.  The widespread role of these neurotransmitters helps to explain the long list of Effexor side effects and withdrawal symptoms. 

                Effexor has a relatively short half-life that helps to explain the severity of the Discontinuation Syndrome (withdrawals) frequently experienced by patients. It is hypothesized that an overly rapid deprivation of multiple neurotransmitter levels contributes to the high rate of withdrawals.

                Effexor Withdrawal Symptoms, Side Effects, Adverse Reactions

                EFFEXOR WITHDRAWAL SYMPTOMS MAY INCLUDE:

                aggression, anxiety, balance issues , blurred vision, brain zaps, concentration impairment, constipation, crying spells, depersonalization, diarrhea, dizziness. electric shock sensations, fatigue, flatulence, flu-like symptoms, hallucinations, hostility, highly emotional, indigestion, irritability, impaired speech, insomnia, jumpy nerves, lack of coordination, lethargy, migraine headaches / increased headaches, nausea, nervousness, over-reacting to situations, paranoia, repetitive thoughts or songs, sensory & sleep disturbances, severe internal restlessness (akathisia), stomach cramps, tremors, tinnitus (ear ringing or buzzing), tingling sensations, troubling thoughts, visual hallucinations / illusions, vivid dreams, speech or visual changes, worsened depression

                EFFEXOR ABRUPT DISCONTINUATION SYMPTOMS MAY INCLUDE:

                agitation, anxiety, confusion, irritability, sensory disturbances, electric shock sensations, dysphoric mood, headache, emotional liability, insomnia, hypomania, tinnitus, seizures, impaired coordination, diarrhea, dizziness, nausea, nervousness, nightmares, somnolence, tremor, vertigo and vomiting

                EFFEXOR SIDE EFFECTS MAY INCLUDE:

                abnormal dreams, abnormal ejaculation or orgasm, anxiety, appetite loss, blurred vision, chills, constipation, diarrhea, dizziness, dry mouth, frequent urination, flushing, gas, headache, impotence, infection, insomnia, muscle tension, nausea, nervousness, rash, sleepiness, sweating, tingling feeling, tremor, upset stomach, vomiting, weakness, yawning, abnormal taste, abnormal thinking, agitation, chest pain, confusion, decreased sex drive, depression, dilated pupils, dizziness upon standing up, high blood pressure, itching, loss of identity, rapid heartbeat, ringing in the ears, trauma, twitching, urinary problems, weight loss

                EFFEXOR ADVERSE REACTIONS MAY INCLUDE: per PDR

                Severe: peptic ulcer, bradycardia, laryngospasm, exfoliative dermatitis, seizures, muscle paralysis, Guillain-Barre syndrome, torticollis, akinesia, stroke, obstruction, heart failure, myocardial infarction , AV block, hematemesis, tendon rupture, cholecystitis, pulmonary embolism, laryngeal edema , apnea, spontaneous fetal abortion, anuria, oliguria , hyperkalemia, prostatic hypertrophy, proteinuria, tardive dyskinesia, suicidal ideation, pancreatitis, ventricular tachycardia, cardiomyopathy, torsade de pointes , ventricular fibrillation, atrial fibrillation, ocular hypertension, serotonin syndrome, neuroleptic malignant syndrome, SIADH, GI bleeding, habdomyolysis, hepatic failure, hepatic necrosis, eosinophilic pneumonia, aplastic anemia , pancytopenia, agranulocytosis, Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), erythema multiforme, angioedema, toxic epidermal necrolysis, Stevens-Johnson syndrome, anaphylactoid reactions, renal failure (unspecified), neonatal abstinence syndrome

                Moderate: ejaculation dysfunction, constipation, hypertension, blurred vision, impotence (erectile dysfunction), hypertonia, depression, confusion , sinus tachycardia, hostility, hallucinations, psychosis, euphoria, peripheral neuropathy, akathisia, ataxia, neuropathic pain, dysarthria, neuritis, hyperesthesia, hypotonia, gastritis, stomatitis, hemorrhoids,, colitis, oral ulceration, glossitis, dysphagia, esophagitis, teeth grinding (bruxism), hypotension, orthostatic hypotension, angina, peripheral vasoconstriction, phlebitis, photophobia, conjunctivitis, cataracts, melena, bone pain, myasthenia, synovitis, hyperlipidemia, hypercholesterolemia, dysphonia, thrombocytopenia, anemia, lymphadenopathy, leukopenia, psoriasis, contact dermatitis, urinary incontinence, vaginal bleeding, urinary retention, hypokalemia, hyperglycemia, withdrawal, mania, impulse control symptoms, dystonic reaction, paresis, aphasia, hyperreflexia, nystagmus, parotitis , proctitis, bundle-branch block, hyponatremia, prolonged bleeding time, hepatitis, jaundice, cholelithiasis, hypoventilation, hemoptysis, hypoxia , lymphocytosis, eosinophilia, flank pain, hypercalciuria, glycosuria, nephrolithiasis, hyperthyroidism, galactorrhea, goiter, hypothyroidism, hypophosphatemia, diabetes mellitus, hyperuricemia, hyperphosphatemia, hypoglycemia, gout, amnesia, trismus, chest pain (unspecified), edema, vaginitis, prostatitis, delirium, dyskinesia, supraventricular tachycardia (SVT), QT prolongation, growth inhibition, priapism, bleeding, platelet dysfunction, elevated hepatic enzymes, steatosis, dyspnea, neutropenia, hyperprolactinemia

                Mild: nausea, weight loss, headache, insomnia, drowsiness, xerostomia, dizziness, hyperhidrosis, weakness, anorexia, asthenia, yawning, diarrhea, libido decrease, dyspepsia, anxiety, vomiting, infection, tremor, orgasm dysfunction, flushing, agitation, paresthesias, flatulence, rash, increased urinary frequency, chills, emotional lability, hyperkinesis, gingivitis, syncope, xerophthalmia, diplopia, arthralgia, muscle cramps, epistaxis.  hyperventilation, laryngitis, leukocytosis, acne vulgaris, maculopapular rash, urticaria, alopecia, xerosis, pruritus, photosensitivity, hirsutism, urinary urgency , nocturia, polyuria, menorrhagia, amenorrhea, mastalgia, fever, paranoia, hyporeflexia, tongue discoloration, cheilitis, hypersalivation, pallor, petechiae , purpura, breast enlargement, gynecomastia, breast discharge, vertigo, dysgeusia, eructation, mydriasis, menstrual irregularity, restlessness, night sweats, ecchymosis, cough

                EFFEXOR BOXED WARNINGS: per PDR

                Children, growth inhibition, suicidal ideation

                Venlafaxine is not FDA approved for the treatment of major depressive disorder (MDD) in children. In October 2004, the FDA directed manufacturers of all antidepressants to add a boxed warning to their product labels detailing the risk of suicide in pediatric patients. The risk of suicidality for these drugs was identified in a pooled analysis of 24 placebo-controlled trials (n = 4,400) lasting up to 16 weeks in pediatric patients with MDD, obsessive compulsive disorder (OCD), or other psychiatric disorders. The analysis showed a greater risk of suicidality during the first few months of treatment in those receiving antidepressants. The average risk of such events on drug was 4% and 2% for placebo; however, no suicides occurred in these trials. Pooled analysis of short-term clinical trials during early phase treatment with antidepressants in young adults (18 to 24 years) also showed an increased risk of suicidal thinking and behavior. The clinical need for an antidepressant in pediatrics or young adults for any use must be weighed against the risk of increased suicidality; patients who are started on therapy should be observed closely for clinical worsening, suicidality, or unusual changes in behavior, particularly within the first few months of starting therapy or during dose changes. It is unknown if the suicidality risk in children or young adults extends to longer-term therapy. The possibility of a suicide attempt is inherent in patients with depressive symptoms, whether these occur in primary depression or in association with another primary disorder. All patients with a history of suicidal ideation or behaviors and those with a prominence of suicidal ideation prior to treatment should be closely monitored during treatment with venlafaxine. In patients who exhibit worsening of depression or suicidality, a decision should be made to change or discontinue treatment. If discontinuing, the medication should be tapered as rapidly as possible, but with recognition that abrupt discontinuation can also cause adverse symptoms. All antidepressants should be prescribed in the smallest quantity consistent with good patient management to reduce the risk of overdose. Postmarketing data suggest that overdose with venlafaxine may result in more serious outcomes (i.e., fatalities) compared to selective serotonin reuptake inhibitors (SSRIs), but less than for tricyclic antidepressants (TCAs). Most reports of overdose have included ingestion of a combination of drugs, including alcohol. Venlafaxine has been shown to lead to dose-dependent weight loss in children ages 6 to 17 years. In addition, growth inhibition has been noted in short and long-term studies in children. Clinicians should regularly monitor height and weight changes in pediatric patients receiving venlafaxine.

                Effexor References and Information

                According to the FDA:

                Serotonin Syndrome: Risk increases with concomitant use of other serotonergic drugs. Discontinue Effexor XR and initiate supportive treatment if serotonin syndrome occurs

                Discontinuation [Symptoms]

                Advise patients not to stop taking Effexor XR without talking first with their healthcare professional. Patients should be aware that discontinuation effects may occur when stopping Effexor XR [see Warnings and Precautions (5.7) and Adverse Reactions (6.1)]. When discontinuing treatment, reduce the dose gradually (2.8, 5.7).


                DISCLAIMER:

                *While great care has been taken in organizing and presenting the material throughout this website, please note that it is provided for informational purposes only and should not be taken as Medical Advice.

                *The statements on this website have not been evaluated by the Food and Drug Administration (FDA). The products and labels mentioned / sold are not intended to diagnose, treat, cure, or prevent any disease or illness.

                * Testimonial results may vary person to person.

                *The program outlined in Point of Return is not meant to substitute your doctor, instead it is to be utilized with your physician to help you with your drug withdrawal process and with his or her consent.

                *Because prescription medications can cause severe withdrawal reactions, do not stop taking any medication without first consulting your physician. The decision to taper any medication should be discussed with your doctor and done with their consent and support. More..